Teva Pharmaceuticals
TEVA
583 hedge funds and large institutions have $14.7B invested in Teva Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 98 funds opening new positions, 194 increasing their positions, 190 reducing their positions, and 46 closing their positions.
113% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 46
81% more call options, than puts
Call options by funds: $727M | Put options by funds: $402M
30% more capital invested
Capital invested by funds: $11.3B → $14.7B (+$3.42B)
29% more funds holding in top 10
Funds holding in top 10: 28 → 36 (+8)
8% more funds holding
Funds holding: 542 → 583 (+41)
2.56% more ownership
Funds ownership: 56.13% → 58.69% (+2.6%)
2% more repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 190
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$350M |
| 2 |
DFO
Duquesne Family Office
New York
|
+$138M |
| 3 |
BlackRock
New York
|
+$123M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$80.4M |
| 5 |
PC
PointState Capital
New York
|
+$68.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$144M |
| 2 |
Millennium Management
New York
|
-$95.9M |
| 3 |
SPC
Slate Path Capital
New York
|
-$94.2M |
| 4 |
Neuberger Berman Group
New York
|
-$70.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$49.3M |
TEVA Hedge Fund Activity: Q4 2024 in Review
583 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2024, worth a combined $14.7B — up 30% from $11.3B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new TEVA positions and 46 closed out — a net gain of 52 holders — while 194 added to existing stakes and 190 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $350M. The largest seller was Arrowstreet Capital, cutting an estimated $144M.
- 583 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2024, up from 542 in Q3 2024.
- Funds reported $14.7B of Teva Pharmaceuticals stock for Q4 2024, up 30% quarter-over-quarter.
- 98 funds opened new Teva Pharmaceuticals positions in Q4 2024 and 46 closed out, a net change of +52 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $350M added.
- The largest Teva Pharmaceuticals seller in Q4 2024 was Arrowstreet Capital, an estimated $144M sold.
Based on aggregated 13F filings for Q4 2024.